![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
ML Ogletree, DN Harris, WA Schumacher, ML Webb and RN Misra
Department of Cardiovascular Pharmacology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey.
180,291 1S-(1 alpha, 2 alpha, 3 alpha, 4 alpha)-2-[[3-[4- [(pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept- 2- yl]methyl]benzenepropanoic acid (BMS) is a potent and highly selective antagonist of thromboxane A2/prostaglandin endoperoxide (TP) receptors. In human platelet-rich plasma, BMS 180,291 inhibited platelet aggregation induced by arachidonate (800 microM) and U-46,619 (10 microM) with respective IC50 values of 7 +/- 1 (S.E.M.) and 21 +/- 2 nM. Inhibition of both the rate and full extent of 11,9-epoxymethano- prostaglandin H2 (U-46,619)-induced platelet aggregation were insurmountable at antagonist concentrations > 10 nM, but BMS 180,291 antagonized U-46,619-induced platelet shape change competitively with a KB of 11 +/- 2 nM. BMS 180,291 concentrations < or = 1 mM did not inhibit platelet aggregation induced by high concentrations of ADP (20 microM) or human alpha-thrombin (1 U/ml). BMS 180,291 inhibited binding of [3H]1S-[1 alpha,2 alpha(5Z),3 alpha,4 alpha]-7-[3-[[2- [(phenylamino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]-hept-2- yl]-5-heptenoic acid to human platelet membranes with a kd of 4.0 +/- 1.0 nM and slope factor of 1.06 +/- 0.13. U-46,619-induced concentrations of rat aortae were competitively antagonized by BMS 180,291 with a KB of 0.6 +/- 0.1 nM. Aortic responses to norepinephrine, serotonin and angiotensin II were not inhibited by BMS 180,291 at 1 microM. U-46,619-induced contractions of guinea pig tracheal rings were antagonized in an almost all-or-none manner, with maximal blockade at > or = 1 nM BMS 180,291, but little effect at lower concentrations.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  C. Bode and M. Zehender The use of antiplatelet agents following percutaneous coronary intervention: focus on late stent thrombosis Eur. Heart J. Suppl., August 1, 2007; 9(suppl_D): D10 - D19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Husted New developments in oral antiplatelet therapy Eur. Heart J. Suppl., August 1, 2007; 9(suppl_D): D20 - D27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Wang, T. Chabrashvili, and C. S. Wilcox Enhanced Contractility of Renal Afferent Arterioles From Angiotensin-Infused Rabbits: Roles of Oxidative Stress, Thromboxane Prostanoid Receptors, and Endothelium Circ. Res., June 11, 2004; 94(11): 1436 - 1442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kitiyakara, W. J. Welch, J. G. Verbalis, and C. S. Wilcox Role of thromboxane receptors in the dipsogenic response to central angiotensin II Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2002; 282(3): R865 - R869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Dockens, K. S. Santone, J. G. Mitroka, R. A. Morrison, M. Jemal, D. S. Greene, and R. H. Barbhaiya Disposition of Radiolabeled Ifetroban in Rats, Dogs, Monkeys, and Humans Drug Metab. Dispos., August 1, 2000; 28(8): 973 - 980. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. J. Welch, B. Peng, K. Takeuchi, K. Abe, and C. S. Wilcox Salt loading enhances rat renal TxA2/PGH2 receptor expression and TGF response to U-46,619 Am J Physiol Renal Physiol, December 1, 1997; 273(6): F976 - F983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Wilcox, H. Gao, J. G. Verbalis, and W. J. Welch Role of AVP in pressor responses during activation of central TxA2/PGH2 receptors Am J Physiol Heart Circ Physiol, October 1, 1997; 273(4): H1927 - H1932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Askari, C. P. Bell-Quilley, D. Fulton, J. Quilley, and J. C. McGiff Analysis of Eicosanoid Mediation of the Renal Functional Effects of Hyperchloremia, J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 101 - 107. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. H. Sigmon and W. H. Beierwaltes Endothelium-Derived Constricting Factor in Renovascular Hypertension Hypertension, April 1, 1995; 25(4): 803 - 808. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
